## Kindly add the following new claims:

--30. A pharmaceutical composition comprising a therapeutically effective amount of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells and a pharmaceutically acceptable carrier therefor,

said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine, said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of the liposome through a maleimide group,

said antibody fragment belonging to IgG class or IgM class and specifically binding to a -surface antigen of a stomach and colon cancer cell membrane, and

said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:5 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:6.

- 31. The pharmaceutical composition of claim 30, wherein the phosphatidylethanolamine is maleimidated phosphatidylethanolamine.
- 32. The pharmaceutical composition of claim 30, wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine.

- The pharmaceutical composition of claim 30, wherein the anti-cancer agent or toxin to cancer is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, aclacinomycin, ricin A and diphtheria toxin.
- 34. The pharmaceutical composition of claim 30, wherein the monoclonal antibody fragment is a F(ab')<sub>2</sub> antibody fragment.
- 35. A pharmaceutical composition comprising a therapeutically effective amount of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells and a pharmaceutically acceptable carrier therefor,

said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine, said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of the liposome through a maleimide group,

said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane,

said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:11 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:12.

36. The pharmaceutical composition of claim 35, wherein the phosphatidylethanolamine is maleimidated phosphatidylethanolamine.

- 37. The pharmaceutical composition of claim 35, wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine.
- 38. The pharmaceutical composition of claim 35, wherein the anti-cancer agent or toxin to cancer is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, aclacinomycin, ricin A and diphtheria toxin.
- The pharmaceutical composition of claim 35, wherein the monoclonal antibody fragment is a  $F(ab')_2$  antibody fragment.
- 40. A liposome/antibody conjugate consisting essentially of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells,

said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine, said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of a liposome through a maleimide group,

said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane, and

said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:5 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:6.

- 41. The liposome/antibody conjugate of claim 40, wherein the phosphatidylethanolamine is maleimidated phosphatidylethanolamine.
- 42. The liposome/antibody conjugate of claim 40, wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine.
- The liposome/antibody conjugate of claim 40, wherein the anti-cancer agent or toxin to cancer is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, aclacinomycin, ricin A and diphtheria toxin.
- 44. The liposome/antibody conjugate of claim 40, wherein the monoclonal antibody fragment is a F(ab')<sub>2</sub> antibody fragment.
- 45. A liposome/antibody conjugate consisting essentially of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells,

said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine, said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of a liposome through a maleimide group,

said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane, and

said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:11 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:12.

- 46. The liposome/antibody conjugate of claim 45, wherein the phosphatidylethanolamine is maleimidated phosphatidylethanolamine.
- 47. The liposome/antibody conjugate of claim 45, wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine.
- 48. The liposome/antibody conjugate of claim 45, wherein the anti-cancer agent or toxin to cancer is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5Fu, aclacinomycin, ricin A and diphtheria toxin.
- 49. The liposome/antibody conjugate of claim 45, wherein the monoclonal antibody fragment is a F(ab')<sub>2</sub> antibody fragment.--

## **REMARKS**

The present paper is presented concurrently with the filing of the above-identified divisional application.